CRL

Business Profile & Competitive Position

Charles River Laboratories International, Inc. operates in the Healthcare sector under the Medical – Diagnostics & Research industry. The company is a full-service, non-clinical drug-development partner: it supplies research model technologies, discovery and safety assessment services, and manufacturing support products across the pharmaceutical and biotechnology pipeline. Its operations are organized into three reportable segments, which in 2025 produced total revenue of $4.0 billion: Research Models and Services (RMS) at 21.1%, Discovery and Safety Assessment (DSA) at 59.8%, and Manufacturing Solutions at 19.1%. With more than 120 sites across more than 20 countries, CRL leverages a broad global footprint to support clients from target identification through non-clinical development and product release.

The quantitative profile, however, tempers any automatic moat conclusion. Trailing net margin is -6.0% and return on equity is -7.7%. Those negative figures mean that, on a reported earnings basis, the business is currently unprofitable rather than generating excess returns. P/E is -57.5, which is not a valuation multiple in the traditional sense but instead reflects negative trailing net income. A leading market position in non-clinical services and an integrated model can produce customer stickiness, yet the recent margin and ROE data imply that pricing power and operating efficiency are under pressure right now. In this context, scale is an asset, but it has not translated recently into a durable earnings-based moat.

Financial Posture

Charles River carries a market capitalization of $13.4 billion and a beta of 1.41, signalling that its shares have historically moved more sharply than the overall market. The negative P/E of -57.5, negative net margin of -6.0%, and negative ROE of -7.7% all point to the same issue: trailing profitability is in the red. As a result, classic trailing-earnings valuation metrics are not especially informative on their own; the market is more likely to be pricing the stock off forward earnings, cash-flow capacity, and the strategic turnaround plan.

The current stock price is $278.06, with a relative strength index (RSI) of 51.3 — a neutral reading — and the 50-day exponential moving average sits at $262.99. Price is therefore above its near-term average. The next scheduled earnings report, on November 4, 2026 before the open, carries an official consensus EPS estimate of $2.96. That estimate will be a key benchmark against which the market measures whether the company is returning to consistent bottom-line growth and whether its cost-efficiency initiatives are gaining traction.

Strategic Priorities & Outlook

According to the company’s most recent SEC 10-K filing, Charles River has a clear near-term operational agenda. First, it intends to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within the DSA and RMS segments. Second, it is integrating Discovery Services and Safety Assessment into a single DSA organization, complete with a combined sales force and leadership structure. Third, it aims to become the scientific partner of choice by delivering a comprehensive and integrated portfolio. Fourth, it continues to pursue opportunities to expand Biologics Testing Solutions service offerings and facilities in the United States and Europe.

A related move came in January 2026, when the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. The Cambodia acquisition underscores the importance of securing research-model supply chains while the broader site-consolidation program points to a management focus on efficiency rather than expansion at any cost. Together, these priorities suggest that the next couple of years will be characterized by restructuring execution, integration, and an effort to convert restructuring savings into improved margins.

Macro & Geopolitical Exposure

As a non-clinical drug-development services provider, Charles River is tied closely to global biopharmaceutical research and development spending. When biotech funding, venture-capital flows, and large-pharma budgets contract, demand for discovery, safety assessment, and outsourced research models typically weakens; when funding rebounds, demand rises. The business is therefore cyclical with respect to life-sciences capital availability even though healthcare itself is a defensive sector.

Other industry-level exposures are regulatory and supply-chain related. Animal research is heavily regulated, and the transport and sourcing of non-human primates can be subject to export/import restrictions, wildlife-trade rules, and public-opinion pressures. Currency risk also matters: operations in more than 20 countries create translation effects for revenue, costs, and intercompany flows. In addition, tariff policy, cross-border logistics, and the availability of specialized reagents and consumables can affect margins. Any tightening of animal-welfare or biosecurity regulations could increase compliance costs or constrain model supply, while tariff disputes could disrupt the international movement of research models and samples.

Recent Developments

Charles River has been active in the headlines in the days leading up to the current snapshot. On September 18, 2026, Zacks published “PGNY vs. CRL: Which Stock Is the Better Value Option?” — a reminder that analysts and investors are actively comparing CRL’s valuation profile against peers. On September 17, 2026, BusinessWire reported that Charles River is leveraging expertise in rapid and in vitro methods to reduce cell-banking timelines, a development tied to its Manufacturing Solutions and broader efficiency narrative. Earlier in the week, on September 15 and September 14, 2026, SeekingAlpha posted transcripts of the company’s presentations at the 2026 Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference, respectively. These investor-conference appearances provided a platform for management to discuss the integration of DSA, site optimization, and the Biologics Testing Solutions expansion strategy.

Earnings Behavior & Post-Earnings Drift

Charles River’s recent earnings record against official estimates is strong. Over the last eight reported quarters, the company has beaten consensus EPS every time, for a beat rate of 8/8 (100%), with an average earnings surprise of 9.3%. The average 5-day price move in the five trading days after those reports has been 1.24%, classified as an “up” drift.

Drilling into the four most recent quarters shows that beats do not always produce a smooth rally. On August 5, 2026, CRL reported actual EPS of $3.02 versus an estimate of $2.74, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five days. The prior quarter, May 7, 2026, produced a $2.06 actual EPS versus a $1.96 estimate, a 5.1% surprise, yet the stock fell 2.23% the next day and dropped 12.42% over the subsequent five sessions. Before that, on February 18, 2026, actual EPS of $2.39 beat the $2.33 estimate by 2.6%, with the stock gaining 3.95% the next day and 6.05% over five days. On November 5, 2025, actual EPS of $2.43 versus a $2.32 estimate, a 4.7% surprise, led to a 1.9% one-day gain and a 2.27% five-day gain.

That pattern highlights two points. First, the official consensus has consistently been too low, producing an average upside surprise of 9.3% across eight quarters. Second, beating the official number is not the same thing as beating the market’s real expectation; the May 2026 reaction shows that a reported beat can be met with a sharp sell-off when guidance, margins, or segment commentary disappoint. With the next report scheduled for November 4, 2026 before the open and the consensus at $2.96, traders will likely weigh the headline EPS number alongside management commentary on site consolidation, DSA integration, and biologics demand.

For a deeper dive into CRL’s valuation, institutional conviction, and how Wall Street is modeling the DSA integration and site-consolidation plan, look at the full institutional verdict to compare analyst ratings, forward estimates, and peer context.